to control my multiple myeloma. My kidney function is impaired and I would like to avoid putting chemicals in my body. Is there anyone out there who can give me some insight to this type of treatment, its effectiveness, past trials???
My oncologist is recommending I take a low dose of Revlimid - any info on effectiveness trials etc?
- Posted:
- 21 Sep 2010 by java1211
- Topics:
- revlimid, multiple myeloma
Responses (1)
15 Oct 2010
REVLIMID contains lenalidomide and when given in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy.
For clinical studies see:
http://www.drugs.com/pro/revlimid.html - scroll down to clinical studies Multiple myeloma.
http://www.revlimid.com/multiple-myeloma/multiple-myeloma-home.aspx
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Similar questions
Confused over blood work results - any suggestions?
26 year old female - I am confused because I have high levels of IgG protein in my blood (1843)... Gamma Globulin (1.7), M-spike (0.7). I was tested ...
My wife, a MM patiant, died leaving some revilimd medication to be disposed of. Revlimid had such?
... stringent handling precautions I'm asking what is the prescribed way to dispose of Revlimid.
I just recently began taking Revlimid with Dex for relapsed multiple myeloma. I take Revlimid 21?
... days (25 mg. daily) and 40 mg of dex. on Monday of each week. Some days are okay however it seems that by the Wednesday after taking the Dex, I ...
Does anyone else form hard, calcified nodules under the skin at the infusion sites with Hizentra?
In March switched from Vivaglobin to Hizentra for hypogammaglobulinemia related to multiple myeloma. No problems with Vivaglobin, but +/- once a ...
Fosamax - does a daily low dose aspirin affect Fosamaz effectiveness?
I take a baby aspirin daily (as recommended by an physician). I have read that anti inflammatory drugs interfere with fosamax. Does this daily low ...
